Paciclovir is an oral small molecule COVID-19 drug. In particular to a treatment method of PF-0732 1332 combined with ritonavir. The former PF-0732 1332 was designed to block the activity of novel coronavirus -3CL protease. Ritonavir is a common HIV drug. The combination of the two drugs can help to slow down the metabolism or decomposition of PF-0732 1332, so that it can maintain a high concentration of activity in the body for a longer time, thus helping to fight the virus.
1. oral liquid is included in the first batch of imported therapeutic drugs in China.
The epidemic situation in China is at a critical stage of prevention and control, and the current world epidemic situation is far from over. The oral liquid contained in the first batch of imported therapeutic drugs in China is to prevent some children or the elderly from being vaccinated because of age discomfort or weak immunity.
Through COVID-19 Oral Liquid, we can get rid of the dependence on vaccines and reach more people to the maximum extent.
2. It means that the global anti-epidemic work has been further developed.
In the early days of COVID-19, China's vaccines mainly depended on domestic production, because there were cases of patients dying in foreign vaccines. With the in-depth study of the virus, various countries have developed various drugs for COVID-19. China's choice of imported drugs shows that no country can be immune to the epidemic, and people must work together to fight the virus and develop more efficient and faster vaccines.
3. It is more convenient to use therapeutic drugs in COVID-19.
According to the company's statistics, the effectiveness of therapeutic drugs in COVID-19 is relatively high, and people can buy related drugs in pharmacies without going to the hospital.
In any case, the epidemic is far from over. In daily life and work, we still need to pay attention to personal hygiene and keep a distance from others.